Skip to main content
Top
Published in: Journal of Translational Medicine 1/2008

Open Access 01-12-2008 | Research

Anti-angiogenic effect of high doses of ascorbic acid

Authors: Nina A Mikirova, Thomas E Ichim, Neil H Riordan

Published in: Journal of Translational Medicine | Issue 1/2008

Login to get access

Abstract

Pharmaceutical doses of ascorbic acid (AA, vitamin C, or its salts) have been reported to exert anticancer activity in vitro and in vivo. One proposed mechanism involves direct cytotoxicity mediated by accumulation of ascorbic acid radicals and hydrogen peroxide in the extracellular environment of tumor cells. However, therapeutic effects have been reported at concentrations insufficient to induce direct tumor cell death. We hypothesized that AA may exert anti-angiogenic effects. To test this, we expanded endothelial progenitor cells (EPCs) from peripheral blood and assessed, whether or not high dose AA would inhibit EPC ability to migrate, change energy metabolism, and tube formation ability. We also evaluated the effects of high dose AA on angiogenic activities of HUVECs (human umbilical vein endothelial cells) and HUAECs (human umbilical arterial endothelial cells). According to our data, concentrations of AA higher than 100 mg/dl suppressed capillary-like tube formation on Matrigel for all cells tested and the effect was more pronounced for progenitor cells in comparison with mature cells. Co-culture of differentiated endothelial cells with progenitor cells showed that there was incorporation of EPCs in vessels formed by HUVECs and HUAECs. Cell migration was assessed using an in vitro wound healing model. The results of these experiments showed an inverse correlation between AA concentrations relative to both cell migration and gap filling capacity. Suppression of NO (nitric oxide) generation appeared to be one of the mechanisms by which AA mediated angiostatic effects. This study supports further investigation into non-cytotoxic antitumor activities of AA.
Appendix
Available only for authorised users
Literature
1.
go back to reference Duconge J, Miranda-Massari JR, Gonzalez MJ, Jackson JA, Warnock W, Riordan NH: Pharmacokinetics of vitamin C: insights into the oral and intravenous administration of ascorbate. P R Health Sci J. 2008, 27 (1): 7-19.PubMed Duconge J, Miranda-Massari JR, Gonzalez MJ, Jackson JA, Warnock W, Riordan NH: Pharmacokinetics of vitamin C: insights into the oral and intravenous administration of ascorbate. P R Health Sci J. 2008, 27 (1): 7-19.PubMed
2.
go back to reference Gonzalez MJ, Miranda-Massari JR, Mora EM, Guzman A, Riordan NH, Riordan HD, Casciari JJ, Jackson JA, Roman-Franco A: Orthomolecular oncology review: Ascorbic acid and cancer 25 years later. Integrative cancer therapies. 2005, 4 (1): 32-44. 10.1177/1534735404273861.CrossRefPubMed Gonzalez MJ, Miranda-Massari JR, Mora EM, Guzman A, Riordan NH, Riordan HD, Casciari JJ, Jackson JA, Roman-Franco A: Orthomolecular oncology review: Ascorbic acid and cancer 25 years later. Integrative cancer therapies. 2005, 4 (1): 32-44. 10.1177/1534735404273861.CrossRefPubMed
3.
go back to reference Peterkofsky B, Prather W: Cytotoxicity of ascorbate and other reducing agents towards cultured fibroblasts as a result of hydrogen peroxide formation. J Cell Physiol. 1977, 90: 61-70. 10.1002/jcp.1040900109.CrossRefPubMed Peterkofsky B, Prather W: Cytotoxicity of ascorbate and other reducing agents towards cultured fibroblasts as a result of hydrogen peroxide formation. J Cell Physiol. 1977, 90: 61-70. 10.1002/jcp.1040900109.CrossRefPubMed
4.
go back to reference Jampel HD: Ascorbic acid is cytotoxic to dividing human tenon's capsule fibroblasts. Arch Ophthalmol. 1990, 108 (9): 1323-1325.CrossRefPubMed Jampel HD: Ascorbic acid is cytotoxic to dividing human tenon's capsule fibroblasts. Arch Ophthalmol. 1990, 108 (9): 1323-1325.CrossRefPubMed
5.
go back to reference Arakama N, Nemoto S, Suzuki E, Otsuka M: Role of hydrogen peroxide in the inhibitory effect of ascorbate on cell growth. J Nutr Sci Vitaminol. 1994, 40: 219-227.CrossRef Arakama N, Nemoto S, Suzuki E, Otsuka M: Role of hydrogen peroxide in the inhibitory effect of ascorbate on cell growth. J Nutr Sci Vitaminol. 1994, 40: 219-227.CrossRef
6.
go back to reference Casciari JJ, Riordan NH, Schmidt TL, Meng XL, Jackson JA, Riordan HD: Cytotoxicity of ascorbate, lipoic acid and other antioxidants in hollow fiber in vitro tumors. Br J Cancer. 2001, 84: 1544-1550. 10.1054/bjoc.2001.1814.PubMedCentralCrossRefPubMed Casciari JJ, Riordan NH, Schmidt TL, Meng XL, Jackson JA, Riordan HD: Cytotoxicity of ascorbate, lipoic acid and other antioxidants in hollow fiber in vitro tumors. Br J Cancer. 2001, 84: 1544-1550. 10.1054/bjoc.2001.1814.PubMedCentralCrossRefPubMed
7.
go back to reference Chen Qi, Espey MG, Krishna MC, Mitchel JB, Copre CP, Buettner GR, Shacter E, Levine M: Pharmacologic ascorbic acid concentrations selectively kill cancer cells: Action as a prodrug to deliver hydrogen peroxide to tissue. PNAS. 2005, 102 (38): 13604-13609. 10.1073/pnas.0506390102.PubMedCentralCrossRefPubMed Chen Qi, Espey MG, Krishna MC, Mitchel JB, Copre CP, Buettner GR, Shacter E, Levine M: Pharmacologic ascorbic acid concentrations selectively kill cancer cells: Action as a prodrug to deliver hydrogen peroxide to tissue. PNAS. 2005, 102 (38): 13604-13609. 10.1073/pnas.0506390102.PubMedCentralCrossRefPubMed
8.
go back to reference Clement MV, Ramalingam J, Long LH, Hallwell B: The in vitro cytotoxicity of ascorbate depends on the culture medium used to perform the assay and involves hydrogen peroxide. Antioxidants and redox signaling. 2001, 3 (1): 157-162. 10.1089/152308601750100687.CrossRefPubMed Clement MV, Ramalingam J, Long LH, Hallwell B: The in vitro cytotoxicity of ascorbate depends on the culture medium used to perform the assay and involves hydrogen peroxide. Antioxidants and redox signaling. 2001, 3 (1): 157-162. 10.1089/152308601750100687.CrossRefPubMed
9.
go back to reference Sestili R, Brandi G, Bramilla L, Cattabeni F, Cantoni O: Hydrogen peroxide mediates the killing of U937 tumor cells elicited by pharmacologically attainable concentrations of ascorbic acid: cell death prevention by extracellular catalase or catalase from cocultured erythrocytes or fibroblasts. The Journal of Pharmacology and experimental therapeutics. 1996, 277: 11719-1725. Sestili R, Brandi G, Bramilla L, Cattabeni F, Cantoni O: Hydrogen peroxide mediates the killing of U937 tumor cells elicited by pharmacologically attainable concentrations of ascorbic acid: cell death prevention by extracellular catalase or catalase from cocultured erythrocytes or fibroblasts. The Journal of Pharmacology and experimental therapeutics. 1996, 277: 11719-1725.
10.
go back to reference Mikirova NA, Jackson JA, Riordan NH: The effect of high dose IV vitamin C on plasma antioxidant capacity and level of oxidative stress in cancer patients and healthy volunteers. JOM. 2007, 22 (3): 153-160. Mikirova NA, Jackson JA, Riordan NH: The effect of high dose IV vitamin C on plasma antioxidant capacity and level of oxidative stress in cancer patients and healthy volunteers. JOM. 2007, 22 (3): 153-160.
11.
go back to reference Riordan NH, Riordan HD, Jackson JA, Casciari JP: Clinical and experimental experiences with intravenous vitamin C. Journal of Orthomolecular Medicine. 2000, 15 (4): 201-213. Riordan NH, Riordan HD, Jackson JA, Casciari JP: Clinical and experimental experiences with intravenous vitamin C. Journal of Orthomolecular Medicine. 2000, 15 (4): 201-213.
12.
go back to reference Riordan HD, Jackson JA, Riordan NH: High-dose intravenous vitamin C in the treatment of patients with renal carcinoma of the kidney. J Orthomolecular Med. 1998, 13: 72-3. Riordan HD, Jackson JA, Riordan NH: High-dose intravenous vitamin C in the treatment of patients with renal carcinoma of the kidney. J Orthomolecular Med. 1998, 13: 72-3.
13.
go back to reference Riordan HD, Riordan NH, Jackson JA, Casciari JJ, Hunninghake R, Gonzalez MJ, Mora EM, Miranda-Massari JR, Rosario N, Rivera A: Intravenous vitamin C as a chemotherapy agent: a report on clinical cases. P R Health Sci J. 2004, 23 (2): 115-118.PubMed Riordan HD, Riordan NH, Jackson JA, Casciari JJ, Hunninghake R, Gonzalez MJ, Mora EM, Miranda-Massari JR, Rosario N, Rivera A: Intravenous vitamin C as a chemotherapy agent: a report on clinical cases. P R Health Sci J. 2004, 23 (2): 115-118.PubMed
14.
go back to reference Jackson JA, Riordan HD, Hunninghake RE, Riordan NH: High-dose intravenous vitamin C and long-time survival of patients with cancer of the head and pancreas. J Orthomol Med. 1995, 10: 87-8. Jackson JA, Riordan HD, Hunninghake RE, Riordan NH: High-dose intravenous vitamin C and long-time survival of patients with cancer of the head and pancreas. J Orthomol Med. 1995, 10: 87-8.
15.
go back to reference Riordan NH, Jackson JA, Riordan HD: Intravenous vitamin C in a terminal cancer patient. J Orthomol Med. 1996, 11: 80-2. Riordan NH, Jackson JA, Riordan HD: Intravenous vitamin C in a terminal cancer patient. J Orthomol Med. 1996, 11: 80-2.
16.
go back to reference Padayatty SJ, Riordan HD, Hewitt SM, Katz A, Hoffer LJ, Levine M: Intravenously administered vitamin C as cancer therapy: three cases. CMAJ. 2006, 174 (7): 937-42.PubMedCentralCrossRefPubMed Padayatty SJ, Riordan HD, Hewitt SM, Katz A, Hoffer LJ, Levine M: Intravenously administered vitamin C as cancer therapy: three cases. CMAJ. 2006, 174 (7): 937-42.PubMedCentralCrossRefPubMed
17.
go back to reference Yeom Hwan Chang, Jung Chul Gyou, Song Jeong Keun: Changes of the terminal cancer patients' health-related quality of life after high dose vitamin C administration. J Korean Med Sci. 2007, 22: 7-11.PubMedCentralCrossRefPubMed Yeom Hwan Chang, Jung Chul Gyou, Song Jeong Keun: Changes of the terminal cancer patients' health-related quality of life after high dose vitamin C administration. J Korean Med Sci. 2007, 22: 7-11.PubMedCentralCrossRefPubMed
18.
go back to reference Du WD, Yuan ZR, Sun J, Tang JX, Cheng AO, Shen DM, Huang CJ, Song XH, Yu XF, Zheng SB: Therapeutic efficacy of high-dose vitamin C on acute pancreatitis and its potential mechanism. World Journal of gastroenterology. 2003, 9 (11): 2565-2569.PubMed Du WD, Yuan ZR, Sun J, Tang JX, Cheng AO, Shen DM, Huang CJ, Song XH, Yu XF, Zheng SB: Therapeutic efficacy of high-dose vitamin C on acute pancreatitis and its potential mechanism. World Journal of gastroenterology. 2003, 9 (11): 2565-2569.PubMed
19.
go back to reference Bagley RG, Walter-Yohrling J, Cao X, Weber W, Simons B, Cook BP, Chartrand SD, Wang C, Madden SL: Endothelial precursor cells as a model of tumor endothelium: Characterization and comparison with mature endothelial cells. Cancer research. 2003, 63: 5866-5873.PubMed Bagley RG, Walter-Yohrling J, Cao X, Weber W, Simons B, Cook BP, Chartrand SD, Wang C, Madden SL: Endothelial precursor cells as a model of tumor endothelium: Characterization and comparison with mature endothelial cells. Cancer research. 2003, 63: 5866-5873.PubMed
20.
go back to reference Peichev M, Naiyer A, Pereira D, Zhu Z, Lane WJ, Williams M, Oz MC, Hicklin DJ, Witte L, Moore MA, Rafii S: Expression of VEGFR2 and AC133 by circulating human CD34+ cells identifies a population of functional endothelial precursors. Blood. 2000, 95: 952-958.PubMed Peichev M, Naiyer A, Pereira D, Zhu Z, Lane WJ, Williams M, Oz MC, Hicklin DJ, Witte L, Moore MA, Rafii S: Expression of VEGFR2 and AC133 by circulating human CD34+ cells identifies a population of functional endothelial precursors. Blood. 2000, 95: 952-958.PubMed
21.
go back to reference Gill M, Dias S, Hattori K, Rivera M, Hicklin D, Witte L, Girardi L, Yurt R, Himel H, Rafii S: Vascular trauma induced rapid but transient mobilization of VEGFR2+AC133+ endothelial precursor cells. Circ Res. 2001, 88: 167-174.CrossRefPubMed Gill M, Dias S, Hattori K, Rivera M, Hicklin D, Witte L, Girardi L, Yurt R, Himel H, Rafii S: Vascular trauma induced rapid but transient mobilization of VEGFR2+AC133+ endothelial precursor cells. Circ Res. 2001, 88: 167-174.CrossRefPubMed
22.
go back to reference Lyden D, Hattori k, Dias S, Costa C, Blaikie P, Butros L, Chadburn A, Heissiq B, Marks W, Witte L, Wu Y, Hicklin D, Zhu Z, Hackett NR, Crystal RG, Moore MA, Hajjar KA, Manova K, Benezra R, Rafii S: Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med. 2001, 7: 1194-1201. 10.1038/nm1101-1194.CrossRefPubMed Lyden D, Hattori k, Dias S, Costa C, Blaikie P, Butros L, Chadburn A, Heissiq B, Marks W, Witte L, Wu Y, Hicklin D, Zhu Z, Hackett NR, Crystal RG, Moore MA, Hajjar KA, Manova K, Benezra R, Rafii S: Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med. 2001, 7: 1194-1201. 10.1038/nm1101-1194.CrossRefPubMed
23.
go back to reference Barley R, Weber W, Rouleau C, Teicher BA: Pericytes and endothelial precursor cells: cellular interactions and contributions to malignancy. Cancer Res. 2005, 65 (21): 9741-9750. 10.1158/0008-5472.CAN-04-4337.CrossRef Barley R, Weber W, Rouleau C, Teicher BA: Pericytes and endothelial precursor cells: cellular interactions and contributions to malignancy. Cancer Res. 2005, 65 (21): 9741-9750. 10.1158/0008-5472.CAN-04-4337.CrossRef
24.
go back to reference Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, Kearne M, magner M, Isner JM: Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res. 1999, 85: 221-8.CrossRefPubMed Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, Kearne M, magner M, Isner JM: Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res. 1999, 85: 221-8.CrossRefPubMed
25.
go back to reference Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Garey VJ, Richardson AL, Weinberg RA: Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005, 121: 335-348. 10.1016/j.cell.2005.02.034.CrossRefPubMed Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Garey VJ, Richardson AL, Weinberg RA: Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005, 121: 335-348. 10.1016/j.cell.2005.02.034.CrossRefPubMed
26.
go back to reference Bompais H, Chagraoui J, Canron X, Crisan M, Liu XH, Anjo A, Port CT, Leboeuf M, Charbord P, Bikfalvi A, Uzan G: Human endothelial cells derived from circulating progenitors display specific functional properties compared with mature vessel wall endothelial cells. Blood. 2004, 103: 2577-2584. 10.1182/blood-2003-08-2770.CrossRefPubMed Bompais H, Chagraoui J, Canron X, Crisan M, Liu XH, Anjo A, Port CT, Leboeuf M, Charbord P, Bikfalvi A, Uzan G: Human endothelial cells derived from circulating progenitors display specific functional properties compared with mature vessel wall endothelial cells. Blood. 2004, 103: 2577-2584. 10.1182/blood-2003-08-2770.CrossRefPubMed
27.
go back to reference Rajantie I, Ilmonen M, Alminaite A, Ozerdem U, Alitalo K, Salven P: Adult bone-marrow derived cells recruited during angiogenesis comprise precursors for periendothelial vascular mural cells. Blood. 2004, 104: 2084-2086. 10.1182/blood-2004-01-0336.PubMedCentralCrossRefPubMed Rajantie I, Ilmonen M, Alminaite A, Ozerdem U, Alitalo K, Salven P: Adult bone-marrow derived cells recruited during angiogenesis comprise precursors for periendothelial vascular mural cells. Blood. 2004, 104: 2084-2086. 10.1182/blood-2004-01-0336.PubMedCentralCrossRefPubMed
28.
go back to reference De Palma M, Venneri MA, Roca C, Naldini L: Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat Med. 2003, 9: 789-795. 10.1038/nm871.CrossRefPubMed De Palma M, Venneri MA, Roca C, Naldini L: Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat Med. 2003, 9: 789-795. 10.1038/nm871.CrossRefPubMed
29.
go back to reference Conejo-Garcia JR, Benencia F, Courreges MC, Mohamed-Hodley A, Buckanovich RJ, Holtz DO, Jenkins A, Na H, Zhang L, Wagner DS, Katsaros D, Caroll R, Coukos G: Tumor-infiltrating dendritic cells precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat Med. 2004, 10: 950-958. 10.1038/nm1097.CrossRefPubMed Conejo-Garcia JR, Benencia F, Courreges MC, Mohamed-Hodley A, Buckanovich RJ, Holtz DO, Jenkins A, Na H, Zhang L, Wagner DS, Katsaros D, Caroll R, Coukos G: Tumor-infiltrating dendritic cells precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat Med. 2004, 10: 950-958. 10.1038/nm1097.CrossRefPubMed
30.
go back to reference Yang L, deBusk LM, Fukuda K, Fingleto B, Green-Jarvis B, Shyr Y, Matrisian LM, Carbone DP, Lin PC: Expansion of myeloid immune suppressor Gr+CD11+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer cell. 2004, 6: 409-421. 10.1016/j.ccr.2004.08.031.CrossRefPubMed Yang L, deBusk LM, Fukuda K, Fingleto B, Green-Jarvis B, Shyr Y, Matrisian LM, Carbone DP, Lin PC: Expansion of myeloid immune suppressor Gr+CD11+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer cell. 2004, 6: 409-421. 10.1016/j.ccr.2004.08.031.CrossRefPubMed
31.
go back to reference Grant MB, May WS, Caballero S, Brown GA, Guthrie SM, Mames RN, Byrne BJ, Vaught T, Spoerri PE, Peck AB, Scott EW: Adult hematopoietic stem cells provide functional hemangioblast activity during retinal neovascularization. Nat med. 2002, 8: 607-612. 10.1038/nm0602-607.CrossRefPubMed Grant MB, May WS, Caballero S, Brown GA, Guthrie SM, Mames RN, Byrne BJ, Vaught T, Spoerri PE, Peck AB, Scott EW: Adult hematopoietic stem cells provide functional hemangioblast activity during retinal neovascularization. Nat med. 2002, 8: 607-612. 10.1038/nm0602-607.CrossRefPubMed
32.
go back to reference Direkze NC, Hodivala-Dilke K, Jeffery R, Hunt T, Poulsom R, Oukrif D, Alison MR, Wright NA: Bone marrow contribution to tumor associated myofibroblasts and fibroblasts. Cancer Res. 2004, 64: 8492-8495. 10.1158/0008-5472.CAN-04-1708.CrossRefPubMed Direkze NC, Hodivala-Dilke K, Jeffery R, Hunt T, Poulsom R, Oukrif D, Alison MR, Wright NA: Bone marrow contribution to tumor associated myofibroblasts and fibroblasts. Cancer Res. 2004, 64: 8492-8495. 10.1158/0008-5472.CAN-04-1708.CrossRefPubMed
33.
go back to reference Telang S, Clem AL, Eaton JW, Chesney J: Depletion of ascorbic acid restricts angiogenesis and retards tumor growth in a mouse model. Neoplasia. 2007, 9: 47-56. 10.1593/neo.06664.PubMedCentralCrossRefPubMed Telang S, Clem AL, Eaton JW, Chesney J: Depletion of ascorbic acid restricts angiogenesis and retards tumor growth in a mouse model. Neoplasia. 2007, 9: 47-56. 10.1593/neo.06664.PubMedCentralCrossRefPubMed
34.
go back to reference Parsons KK, Maeda N, Yamauchi M, Banes AJ, Koller BH: Ascorbic-acid – independent synthesis of collagen in mice. Am J Physiol Endocrinol Metab. 2006, 290: E1131-1139. 10.1152/ajpendo.00339.2005.CrossRefPubMed Parsons KK, Maeda N, Yamauchi M, Banes AJ, Koller BH: Ascorbic-acid – independent synthesis of collagen in mice. Am J Physiol Endocrinol Metab. 2006, 290: E1131-1139. 10.1152/ajpendo.00339.2005.CrossRefPubMed
35.
go back to reference Peyman GA, Kivilcim M, Dellacroce JT, Munoz Morales A: Inhibition of Corneal Neovascularization by Ascorbic Acid in Rat Model [abstract]. Graefes Arch Clin Exp Ophthalmol. 2007, 245 (10): 1461-1467. 10.1007/s00417-007-0542-4.CrossRefPubMed Peyman GA, Kivilcim M, Dellacroce JT, Munoz Morales A: Inhibition of Corneal Neovascularization by Ascorbic Acid in Rat Model [abstract]. Graefes Arch Clin Exp Ophthalmol. 2007, 245 (10): 1461-1467. 10.1007/s00417-007-0542-4.CrossRefPubMed
36.
go back to reference Tamalarasan KP, Kolluru GK, Rajaram M, Indhumathy M, Saranya R, Chatterjee S: Thalidomide attaenuates nitric oxide mediated angiogenesis by blocking migration of endothelila cells. BMC cell Biology. 2006, 7: 17-30. 10.1186/1471-2121-7-17.CrossRef Tamalarasan KP, Kolluru GK, Rajaram M, Indhumathy M, Saranya R, Chatterjee S: Thalidomide attaenuates nitric oxide mediated angiogenesis by blocking migration of endothelila cells. BMC cell Biology. 2006, 7: 17-30. 10.1186/1471-2121-7-17.CrossRef
37.
go back to reference Lin YI, Weisdorf DJ, Solovey A, Hebbel RP: Origins of circulating endothelial cells and endothelial outgrowth from blood. Journal of clinical Investigation. 2000, 105 (4): 71-77. 10.1172/JCI8071.PubMedCentralCrossRefPubMed Lin YI, Weisdorf DJ, Solovey A, Hebbel RP: Origins of circulating endothelial cells and endothelial outgrowth from blood. Journal of clinical Investigation. 2000, 105 (4): 71-77. 10.1172/JCI8071.PubMedCentralCrossRefPubMed
38.
go back to reference Gulati R, Jevremovic D, Peterson TE, Chatterjee S, Shah V, Vile RG, Simari RD: Diverse origin and function of cells with endothelila phenotype obtained from adult human blood. Circulation Research. 2003, 93: 1023-1025. 10.1161/01.RES.0000105569.77539.21.CrossRefPubMed Gulati R, Jevremovic D, Peterson TE, Chatterjee S, Shah V, Vile RG, Simari RD: Diverse origin and function of cells with endothelila phenotype obtained from adult human blood. Circulation Research. 2003, 93: 1023-1025. 10.1161/01.RES.0000105569.77539.21.CrossRefPubMed
39.
go back to reference Duda DG, Fukumura D, Jain RK: Role of eNOS in neovascularization: NO for endothelial progenitor cells. Trends Mol Med. 2004, 10: 143-145. 10.1016/j.molmed.2004.02.001.CrossRefPubMed Duda DG, Fukumura D, Jain RK: Role of eNOS in neovascularization: NO for endothelial progenitor cells. Trends Mol Med. 2004, 10: 143-145. 10.1016/j.molmed.2004.02.001.CrossRefPubMed
40.
go back to reference Dulak J, Jozkowicz A: Nitric oxide induces the synthesis of vascular endothelial growth factor by rat vascular smooth muscle cells. Arterioscler Thromb Biol. 2000, 20: 659-666.CrossRef Dulak J, Jozkowicz A: Nitric oxide induces the synthesis of vascular endothelial growth factor by rat vascular smooth muscle cells. Arterioscler Thromb Biol. 2000, 20: 659-666.CrossRef
41.
go back to reference Gratton JP, Lin MI, Yu J, Weiss ED, Jiang ZL, Fairchild TA, Iwakiri Y, Groszmann R, Claffey KP, Cheng YC, Sessa WC: Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice. Cancer Cell. 2003, 4: 31-39. 10.1016/S1535-6108(03)00168-5.CrossRefPubMed Gratton JP, Lin MI, Yu J, Weiss ED, Jiang ZL, Fairchild TA, Iwakiri Y, Groszmann R, Claffey KP, Cheng YC, Sessa WC: Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice. Cancer Cell. 2003, 4: 31-39. 10.1016/S1535-6108(03)00168-5.CrossRefPubMed
42.
go back to reference Gallo O, Masini E, Morbidelli L, Franchi A, Fini-Storchi I, Vergari WA: Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. J Natl cancer Inst. 1998, 90: 584-596. 10.1093/jnci/90.8.587.CrossRef Gallo O, Masini E, Morbidelli L, Franchi A, Fini-Storchi I, Vergari WA: Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. J Natl cancer Inst. 1998, 90: 584-596. 10.1093/jnci/90.8.587.CrossRef
43.
go back to reference Lorraine JC, Lala PK: Nitric oxide synthase inhibition by NG-nitro-L-arginine methyl ester inhibits tumor-induced angiogenesis in mammary tumors. Am J Pathol. 1999, 155: 1381-1390.CrossRef Lorraine JC, Lala PK: Nitric oxide synthase inhibition by NG-nitro-L-arginine methyl ester inhibits tumor-induced angiogenesis in mammary tumors. Am J Pathol. 1999, 155: 1381-1390.CrossRef
44.
go back to reference Lee PC, Salyapongse AN, Bragdon GA, Shears LL, Watkins SC, Edington HD, Billiar TR: Impaired wound healing and angiogenesis in e NOS-deficient mice. Am J Physiol. 1999, 277: H1600-H1608.PubMed Lee PC, Salyapongse AN, Bragdon GA, Shears LL, Watkins SC, Edington HD, Billiar TR: Impaired wound healing and angiogenesis in e NOS-deficient mice. Am J Physiol. 1999, 277: H1600-H1608.PubMed
45.
go back to reference Jenkins DC, Charles IG, Thomsen LL, Moss DW, Holmes LS, Baylis SA, Rhodes P, Westmore K, Emson PC, Moncada S: Role of nitric oxide in tumor growth. Proc Natl Acad Sci. 1995, 92: 4392-4396. 10.1073/pnas.92.10.4392.PubMedCentralCrossRefPubMed Jenkins DC, Charles IG, Thomsen LL, Moss DW, Holmes LS, Baylis SA, Rhodes P, Westmore K, Emson PC, Moncada S: Role of nitric oxide in tumor growth. Proc Natl Acad Sci. 1995, 92: 4392-4396. 10.1073/pnas.92.10.4392.PubMedCentralCrossRefPubMed
46.
go back to reference Gratton J, Lin M, Yu J, Weiss E, Jiang ZL, Fairchild TA, Iwakiri Y, Groszmann R, Claffey KP, Cheng YC, Sessa WC: Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice. Cancer cell. 2003, 4: 31-39. 10.1016/S1535-6108(03)00168-5.CrossRefPubMed Gratton J, Lin M, Yu J, Weiss E, Jiang ZL, Fairchild TA, Iwakiri Y, Groszmann R, Claffey KP, Cheng YC, Sessa WC: Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice. Cancer cell. 2003, 4: 31-39. 10.1016/S1535-6108(03)00168-5.CrossRefPubMed
Metadata
Title
Anti-angiogenic effect of high doses of ascorbic acid
Authors
Nina A Mikirova
Thomas E Ichim
Neil H Riordan
Publication date
01-12-2008
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2008
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-6-50

Other articles of this Issue 1/2008

Journal of Translational Medicine 1/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.